CANCER TRIAL PARTICIPATION PGM

Amends the Mental Health and Developmental Disabilities Code. Provides that the Department of State Police shall annually compile and submit a report to the Governor and General Assembly no later than May 31 of each calendar year on the number of persons reported as posing a clear and present danger to themselves or others by persons required to report that information to the Department of State Police under the Code. Provides that the report shall be based on information submitted by each county, municipality, public elementary or secondary school, private elementary or secondary school, or public or private community college, college, or university of the State without disclosing individual identifying information of the persons who pose the clear and present danger to themselves or others. Provides that if the person who poses the clear and present danger is reported by home address and the person attends a school, college, or university, then the compilation shall only include that individual once in the report for the total annual compilation. House Committee Amendment No. 1 Deletes reference to: 405 ILCS 5/6-103.3 Adds reference to: New Act Replaces everything after the enacting clause. Creates the Cancer Clinical Trial Participation Program Act. Presents the findings of the General Assembly. Provides that an independent third-party organization may develop and implement a cancer clinical trial participation program to provide reimbursement to subjects for ancillary costs associated with participation in a cancer clinical trial. Requires the program to collaborate with physicians, health care providers, and cancer clinical trial sponsors to notify a prospective subject about the program, reimburse subjects based on financial need, and provide reimbursement for ancillary costs. Provides that an organization administering the program shall provide written notice to prospective subjects of the requirements. Provides that reimbursement under the program at a trial site that conducts cancer clinical trials must be reviewed and approved by the institutional review board associated with the cancer clinical trial for which the reimbursement is provided and that an organization operating the program is not required to obtain approval from an institutional review board on the financial eligibility of a subject who is medically eligible for the program. Requires an organization operating the program to provide subjects with specified written notice. Provides that reimbursement to a subject of ancillary costs under the program does not constitute an undue inducement to participate in a cancer clinical trial and is not considered coercion or the exertion of undue influence to participate in a cancer clinical trial. Allows an organization that administers the program to accept gifts, grants, and donations from any public or private source to implement the Act. Effective immediately.